Delving into the Latest Updates on Oncoscience AG with Synapse

A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

开始日期2007-09-01

申办/合作机构

Oncoscience AG

[+2]

NCT00753246 / Completed临床3期

Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV

Determination of efficiency of nimotuzumab in adults with glioblastoma multiforma

开始日期2007-08-01

申办/合作机构

Oncoscience AG

[+9]

EUCTR2007-000338-38-DE / Not yet recruitingN/A

A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREAMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

开始日期2007-07-06

申办/合作机构

Oncoscience AG

100 项与 Oncoscience AG 相关的临床结果

登录后查看更多信息

0 项与 Oncoscience AG 相关的专利（医药）

登录后查看更多信息

100 项与 Oncoscience AG 相关的药物交易

登录后查看更多信息

100 项与 Oncoscience AG 相关的转化医学

登录后查看更多信息